Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Perinatal/Neonatal Case Presentation
  • Published:

Perinatal/Neonatal Case Presentation

Use of Recombinant Factor VIIa in Infants with Severe Coagulopathy

Journal of Perinatology volume 24, pages 310–311 (2004)Cite this article

Abstract

The risk of hemorrhage in infants with severe coagulopathies unresponsive to fresh frozen plasma (FFP) infusions may preclude therapeutic invasive interventional procedures. We describe the successful use of recombinant factor VIIa (rFVIIa) in two such infants, the first with cirrhosis requiring paracentesis and the second with necrotizing enterocolitis requiring laparotomy. This report reviews the current concepts on the mechanism of action of the drug rFVIIa and considers its expanded use in infants unresponsive to FFP replacement.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Hedner U . Recombinant coagulation factor VIIa: from the concept to clinical application in hemophilia treatment in 2000. Semin Thromb Hemost 2000;26(4):363–372.

    Article  CAS  Google Scholar 

  2. Negrier C, Hay CRM . The treatment of bleeding in hemophilic patients with inhibitors with recombinant factor VIIa. Semin Thromb Hemost 2000;26(4):407–412.

    Article  CAS  Google Scholar 

  3. Shapiro AD . Recombinant factor VIIa in the treatment of bleeding in hemophilic children with inhibitors. Semin Thromb Hemost 2000;26(4):413–419.

    Article  CAS  Google Scholar 

  4. Van'T Veer C, Mann KG . The regulation of the factor VII-dependent coagulation pathway: rationale for the effectiveness of recombinant factor VIIa in refractory bleeding disorders. Semin Thromb Hemost 2000;26(4):367–372.

    Article  CAS  Google Scholar 

  5. Schulman S . Continuous infusion of recombinant factor VIIa in hemophilic patients with inhibitors: safety, monitoring, and cost effectiveness. Semin Thromb Hemost 2000;26(4):421–424.

    Article  CAS  Google Scholar 

  6. Lucia JF, et al. Successful outcome of a cirrhotic patient with postoperative haematuria treated with a single high dose of recombinant factor VIIa. Haemophilia 2001;7:600–602.

    Article  CAS  Google Scholar 

  7. Greisen G, Andreasen RB . Recombinant factor VIIa in preterm neonates with prolonged prothrombin time. Blood Coagulation Fibrinol 2003;14(1):117–120.

    Article  CAS  Google Scholar 

  8. Tobias JD, Groeper K, Berkenbosch JW . Preliminary experience with the use of recombinant factor VIIa to treat coagulation disturbances in pediatric patients. South Med J 2003;96(1):12–16.

    Article  Google Scholar 

  9. Lisman T, De Groot G . Mechanism of action of recombinant factor VIIa. J Thromb Haemost 2003;1(6):1138.

    Article  CAS  Google Scholar 

  10. Aledort LM . rFVIIa-its thrombogenicity. Thromb Haemost 2000;84:522–523.

    Article  CAS  Google Scholar 

  11. Chuansumrit A, Nuntnarumit P, Okascharoen C, Teeraratkul S, Suwansingh S, Supapannachart S . The use of recombinant activated factor VIIa to control bleeding in a preterm infant undergoing exploratory laparotomy. Pediatrics 2002;107(1):169–171.

    Article  Google Scholar 

  12. Bernstein D . Effectiveness of the recombinant factor VIIa in patients with the coagulopathy of advanced child's B and C cirrhosis. Semin Thromb Hemost 2000;26(4):437–438.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Jennie Ariail, Associate Director of the Center for Academic Excellence at the Medical University of South Carolina, for her thorough review of the manuscript.

Author information

Authors and Affiliations

  1. Department of Pathology, Transfusion Medicine Division, Medical University of South Carolina, Stanford University, Stanford, CA, USA

    Magali J Fontaine MD

  2. Hematopathology Division, Medical University of South Carolina, Stanford University, Stanford, CA, USA

    John Lazarchick MD

  3. Department of Pediatrics, Division of Neonatology, Medical University of South Carolina, SC, USA

    Sarah Taylor MD & David Annibale MD

Authors
  1. Magali J Fontaine MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John Lazarchick MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sarah Taylor MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. David Annibale MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Magali J Fontaine MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fontaine, M., Lazarchick, J., Taylor, S. et al. Use of Recombinant Factor VIIa in Infants with Severe Coagulopathy. J Perinatol 24, 310–311 (2004). https://doi.org/10.1038/sj.jp.7211086

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jp.7211086

This article is cited by

Search

Advanced search

Quick links